Northwest Biotherapeutics Files 8-K on Shareholder Votes

Ticker: NWBO · Form: 8-K · Filed: 2024-07-03T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

NWBO filed an 8-K on shareholder votes as of 6/29. Corporate governance update.

AI Summary

Northwest Biotherapeutics, Inc. filed an 8-K on July 3, 2024, reporting on matters submitted to a vote of security holders as of June 29, 2024. The filing details the company's corporate structure and its principal executive offices located in Bethesda, Maryland.

Why It Matters

This filing provides an update on corporate governance matters, specifically votes by security holders, which can impact company direction and shareholder rights.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing a vote of security holders and does not appear to contain significant new financial or operational risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on matters submitted to a vote of security holders as of June 29, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 29, 2024.

What is the principal executive office address of Northwest Biotherapeutics, Inc.?

The principal executive office address is 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.

What is the company's telephone number?

The company's telephone number is (240) 497-9024.

In which state was Northwest Biotherapeutics, Inc. incorporated?

Northwest Biotherapeutics, Inc. was incorporated in Delaware.

Filing Stats: 1,133 words · 5 min read · ~4 pages · Grade level 9.9 · Accepted 2024-07-03 14:44:18

Key Financial Figures

Filing Documents

07

Item 5.07. Submission of Matters to a Vote of Security Holders. Northwest Biotherapeutics, Inc. (the "Company") held an annual meeting of stockholders on June 29, 2024 (the "Annual Meeting"), at which a quorum was present. The number of shares represented and voting in person or by proxy at the Annual Meeting was 961,690,911, representing 77.48% of the total combined voting power of all outstanding common and preferred stock on the record date for the Annual Meeting. At the Annual Meeting, the stockholders voted on five matters: (1) the re-election of Dr. Alton L. Boynton and Ambassador J. Cofer Black as Class I members of the Board of Directors for a three-year term, (2) ratification of the appointment of Cherry Bekaert LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, (3) ratification of the same option awards that were made in 2020 to the named executive officers and for which the stockholders already voted in favor in an advisory vote at the 2021 Annual Meeting and in a ratification vote at the 2022 Annual Meeting, (4) ratification of the same option awards that were made in 2020 to the non-executive Directors on the Board of Directors, and that were previously reported and previously approved by stockholders at the 2022 Annual Meeting and (5) approval, on an advisory basis, of the Company's 2023 executive compensation. As of the close of business on May 9, 2024, the record date for the Annual Meeting, there were 1,210,879,427 shares of par value $0.001 per share (the "Common Stock") and 1,211,971 shares of Preferred Stock, par value $0.001 (the "Preferred Stock"), entitled to vote at the Annual Meeting. Each share of Common Stock entitled the record holder to one vote on each matter to be voted upon at the Annual Meeting. Each share of Preferred Stock (which is convertible into 25 shares of Common Stock) entitled the record holder to 25 votes on each matter to be voted upon at the Annual Meeti

View on Read The Filing